Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2024-08-29 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房关于回购注销2022年限制性股票激励计划部分限制性股票的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the company's repurchase and cancellation of restricted shares under its 2022 restricted stock incentive plan. It details the number of shares repurchased, prices, approvals from board and shareholders, legal opinions, and the impact on share capital structure. The document is a formal public announcement of a share repurchase related to stock incentives, not a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but focuses on the transaction of repurchasing and cancelling shares. According to the filing definitions, this fits best under 'Transaction in Own Shares' (POS), which covers company buybacks or sales of its own shares. The document length is under 5,000 characters and is a detailed announcement, not just a brief notice or a report publication announcement. Therefore, the classification is POS with high confidence.
2024-08-29 Chinese
益丰药房关于召开2024年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a notice about convening the 2024 third extraordinary general meeting of shareholders for Yifeng Pharmacy Chain Co., Ltd. It includes details about the meeting date, voting methods, agenda items (such as the 2024 semi-annual profit distribution plan), and instructions for shareholders on how to participate and vote. It also contains an authorization proxy form for shareholders to delegate voting rights. There is no financial data or report content, only a meeting notice and procedural information. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings.
2024-08-29 Chinese
益丰药房关于回购注销部分限制性股票通知债权人的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Yifeng Pharmacy Chain Co., Ltd. regarding the repurchase and cancellation of part of its restricted stocks due to employee departures, which will result in a reduction of registered capital. It notifies creditors about their rights to claim debts or request guarantees within a specified period due to the capital change. The document is short (1255 characters) and primarily serves as a notification to creditors about the repurchase and capital reduction, not a detailed financial report or audit. It does not contain financial statements or detailed financial data. This fits the category of a Regulatory Filing (RNS) as it is a formal regulatory announcement about corporate actions affecting capital and creditor rights, but not a full financial report or capital/financing update per se.
2024-08-29 Chinese
益丰药房关于预计触发“益丰转债”转股价格向下修正条件的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from the board of directors of Yifeng Pharmacy Chain Co., Ltd. regarding the expected triggering of a downward adjustment condition for the conversion price of its convertible bonds (益丰转债). It details the bond issuance, terms, the conditions under which the conversion price may be adjusted downward, the procedural requirements for such an adjustment, and a risk warning to investors. The document is an informative notice about a potential future event related to the bond's conversion price adjustment, not a financial report, earnings release, or detailed management discussion. It is also not a full regulatory filing or certification but a specific announcement about capital structure changes related to convertible bonds. Given the content focuses on convertible bond conversion price adjustment conditions and related procedural disclosures, this fits best under Capital/Financing Update (CAP). The document length is 2335 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2024-08-23 Chinese
益丰药房关于归还暂时用于补充流动资金的可转换公司债券募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the repayment of temporarily used raised funds for working capital. It references previous announcements and details the amount repaid and remaining balance. The content is about capital usage and repayment, not a full financial report or earnings release. It is a financing update related to the company's capital structure and use of raised funds. The document length is short and focused on a specific financing activity, fitting the Capital/Financing Update category.
2024-08-16 Chinese
益丰大药房连锁股份有公司关于使用闲置募集资金委托理财到期赎回并继续委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Yifeng Pharmacy Chain Co., Ltd. regarding the redemption of idle raised funds from entrusted financial management products and the continuation of such entrusted financial management. It details the amounts, products, risk analysis, and board approval related to the use of idle raised funds for short-term financial products. The document is a formal public announcement about the company's capital management activities involving raised funds, not a financial report, earnings release, or audit report. It does not contain comprehensive financial statements or quarterly results but focuses on capital usage and investment updates. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and contains detailed information about financing activities rather than just a brief notice or regulatory filing, so it is not RPA or RNS. Hence, the classification is CAP with high confidence.
2024-08-02 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.